San Jose, California (Vocus) 11 June 2010

Bipolar disorder is a chronic and devastating psychiatric disorders. Since neither curable nor treatable effective, the market for bipolar disorder is present with high medical need. The main disadvantages of existing products include dyskinesia, compulsive behaviors and psychiatric side effects and ineffectiveness in the treatment of cognitive deficits, the rapid recovery or depressive symptoms. In addition, if the anticonvulsants (eg valproic acid) and lithium significantly improved the prognosis of the disease, many patients show poor tolerance of side effects associated with treatment. Other major clinical setbacks include lack of respect for the regimen, inadequate clinical response and relapse.

The United States dominates the world of bipolar disorder in the report of the search for new markets established in the market for bipolar disorder. According to the American National Institute of Mental Health, there are approximately 5.7 million adults aged 18 years and suffered from bipolar disorder in the United States. The treatment of bipolar disorder is different from the physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and the prescription of lithium, valproic acid and atypical antipsychotics as first-line monotherapy in bipolar mania, and that the recommended treatment Lamictal for bipolar depression. And, unlike psychiatrists, who follow APA guidelines and prescription Lamictal frontline practitioners choose the first line antidepressants.

bipolar disorder is highly consolidated market with the top five players accounting Liona? s market share. These players are hardly any challenge (s) in the future to meet, all the molecules of the pipeline will provide only symptomatic relief, and no company is developing a therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company Forest Laboratories Inc., Gedeon Richter plc, Glaxo Smith Kline PLC, Company H . Lundbeck A / S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka Pharmaceutical Inc., Pfizer Inc., Repligen and Validus Pharmaceuticals Inc.

The report

? Bipolar Disorder: A Global Strategic Business reported? known by Global Industry Analysts, Inc., offers an analysis of unmet medical needs, opportunities and challenges, patent processes, the competitive position scenario, select leading products to choose pipeline drugs, clinical trials, product approvals / Starts recent activity in the industry and reporting of the main participants in the global market. The study analyzes market data and analysis in terms of value sales for regions where the United States, Europe, Asia-Pacific and the rest of the world. World market is analyzed by the following substance classes: – atypical anti-psychotic and other therapeutic products.

For more details on this market research report, please visit??
http://www.strategyr.com/Bipolar_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a renowned publisher of off-market research in the trade. Founded in 1987, the company is recognized worldwide as one of the world for? Most publishers of market research. The company employs over 800 people worldwide and publishes more than 1,100 large-scale research reports each year. In addition, the company also offers thousands of research products including reports of small businesses, reports on market trends and industry reports include all major industries worldwide.


Industry analysts

Global, Inc.

Tel 408-528-9966

Fax 408-528-9977

email press (at) StrategyR (dot) com
>
Http://www.StrategyR.com/ website

P

###

clear = “all”
Bipolar Disorder